WHAT THIS STUDY ADDS
myocardial injury
This study shows that tocilizumab leads to an increase in IL-6, IL-8 and IL-1ra in patients with STEMI, and it attenuates the correlation of IL-6 and IL-8 with neutrophils/C reactive protein and markers of myocardial injury observed in the placebo group.